Folks Asked Me What I am Doing for Coronavirus Protection -- Lauricidin

Folks Asked Me What I am Doing for Coronavirus Protection -- Lauricidin

On my Wednesday radio show I mentioned that a number of you have been asking me what I am doing in an effort to prepare for Coronavirus.   I pointed out that the Virus has a Lipid Envelope, and that the over-the-counter food supplement Lauricidin seems to dissolve such virus envelopes, killing the virus.  Here's how to get yours:

From Wikipedia:


Monolaurin in capsule form as a dietary supplement

Monolaurin has antibacterialantiviral, and other antimicrobial effects in vitro, but its clinical usefulness has not been established. Monolaurin is currently sold as a dietary supplement and is categorized in the United States by the Food and Drug Administration as generally recognized as safe (GRAS).

Monolaurin is known to inactivate lipid-coated viruses by binding to the lipid-protein envelope of the virus, thereby preventing it from attaching and entering host cells, making infection and replication impossible.[12] Other studies show that Monolaurin disintegrates the protective viral envelope, killing the virus. Monolaurin has been studied to inactivate many pathogens including Herpes simplex virus[15] and Chlamydia trachomatis.[16]

Monolaurin also shows promising effects against bacteria (both gram-positive and gram-negative), yeast, fungi, and protozoa. Bacteria including E. Coli, yeast including Candida albicans, Helicobacter pylori (H. pylori), Giardia lamblia, Staphylococcus aureus (Staph), and other microbials have all been neutralized by monolaurin in scientific studies. Monolaurin also presented antibacterial and anti-biofilm properties against Borrelia burgdorferi and Borrelia garinii, the bacterium which cause Lyme Disease in humans.

Furthermore, monolaurin does not seem to contribute to drug resistance. 


Now, I am NOT a medical Doctor and I cannot give medical advice.  I'm not.   I don't know if the studies mentioned in Wikipedia are correct or not.   

I am simply telling you what Wikipedia says about this food supplement.  You have to decide for yourselves, what to do -- if anything.  

Here is a link to various sources on Ebay of Lauricidin which is the brand name of the product with the active ingredient Monolaurin





The World Health Organization published the results of MULTIPLE medical studies showing people who take 300-2,000 IU of Vitamin D daily, have a very significant reduction of Respiratory infections.   The results were remarkable!   Here is the info from the World Health Organization:


Vitamin D for prevention of respiratory tract infections


Rhaiza Aponte, MSHN and Cristina Palacios, PhD
Nutrition Program, Graduate School of Public Health, Medical Sciences Campus, University of Puerto Rico, San Juan, Puerto Rico
June 2017


Respiratory tract infections are conditions that affect the air passages. These include acute infections that affect the lower respiratory tract and lungs, such as pneumonia and influenza (1), which are among the leading causes of death in children worldwide (2). In 2015, 16% of all deaths in children under five years of age were attributed to pneumonia (2). These conditions may also have an impact on quality of life (3). Therefore, it is important to find interventions that could prevent respiratory conditions.

Vitamin D is a fat-soluble-vitamin, different from others in that a major source derives from UV light-induced conversion of its precursor under the skin. Dietary sources include fortified foods and supplements. Studies have indicated that there is a high prevalence of vitamin D deficiency worldwide (4–5). Vitamin D deficiency may affect the immune system as vitamin D plays an immunomodulation role (6), enhancing innate immunity by up-regulating the expression and secretion of antimicrobial peptides (7–8), which boosts mucosal defences. Furthermore, recent meta-analyses have reported a protective effect of vitamin D supplementation on respiratory tract infections (9–12). Therefore, in this commentary we reviewed the applicability of such intervention and implementation in settings with limited resources based on these four systematic reviews and meta-analyses.

Methodology summary

This commentary provides an overview of four systematic reviews and meta-analyses (9–12). Yakoob et al. (9) conducted a Cochrane review of individually- or cluster-randomized controlled trials assessing synthetic oral vitamin D supplementation and the incidence rate of respiratory tract infection in children under five years of age. This review included trials of vitamin D supplementation at different doses and frequencies compared to a control group. The control group included placebo of propylene glycol or olive oil, or no intervention. The outcomes included in this review were incidence rate, duration, and severity of infections, particularly, pneumonia and diarrhoea. Pneumonia was confirmed by chest radiograph.

Bergman et al. (10) conducted a systematic review and meta-analysis of randomized controlled trials assessing vitamin D and incidence of respiratory tract infection, defined by each author as primary or secondary outcomes, including upper or lower infections in children and in adults; they excluded tuberculosis and fungal infections. The randomized trials compared vitamin D supplementation group to a control (no treatment or placebo) group. In this review, there were no limitations with regard to participant’s characteristics, vitamin D doses, and treatment duration.

Charan et al. (11) assessed the effect of vitamin D supplementation on the prevention of respiratory tract infections through a meta-analysis of randomized placebo controlled clinical trials in children and in adults. The outcome of this systematic review and meta-analysis was the episode of respiratory tract infection (pneumonia, influenza, common cold) in those randomized to the intervention compared to controls.

Martineau et al. (12) completed a systematic review and meta-analysis of randomized controlled trials with individual’s participant data. This review assessed the effect of vitamin D supplementation on acute respiratory tract infections in children and in adults.

These reviews used standard procedure of search terms and strategies, and presented clear search criteria and data analyses for conducting systematic reviews and meta-analyses.

Evidence summary

Yakoob et al. (9) included four trials with a total of 3198 children from Afghanistan, Spain, and the USA. Pneumonia episodes (two trials reported this) were similar between those supplemented with vitamin D compared to controls (Rate Ratio [RR]: 1.06; 95% CI: 0.89, 1.26). The trial from Afghanistan found an increase in repeat episodes of pneumonia with vitamin D supplementation (RR 1.69; 95% CI: 1.28, 2.21) but not when confirmed or unconfirmed pneumonia was combined (RR 1.06; 95% CI: 1.00, 1.13). No study reported on duration of pneumonia or severity of infection.

Bergman et al. (10) included 11 randomized placebo-controlled trials with 5660 individuals (average age was 16 years, ranging from 6 months to 75 years). The summarized results showed that vitamin D supplementation significantly decreased the risk of respiratory tract infections (odds ratio [OR]: 0.64; 95% CI: 0.49, 0.84; p=0.0014). Also, this review found that the protective effect of vitamin D was greater in studies using daily single doses (300-2000 IU/day) (OR 0.51; 95% CI: 0.39, 0.67) compared to large doses given at certain intervals (100,000 or 200,000 IU per month or every 3 months) (OR 0.86; 95% CI: 0.62, 1.20). However, there was evidence of heterogeneity and publication bias among studies.

Five clinical trials were included in the review conducted by Charan et al. (11). The reduction of episodes of respiratory tract infections was significantly lower in vitamin D supplementation group compared to the control group (OR=0.58; 95% CI: 0.42, 0.81; p=0.001). When analysed by age using fixed models, the protective effect of vitamin D supplementation was found among two trials reporting this in children (OR 0.58; 95% CI: 0.42, 0.81; P=0.001 in two trials) and among three trials reporting this in adults (OR 0.65; 95% CI: 0.47, 0.90; P=0.01). However, when using random models, the effect remained significant in children (OR 0.58; 95% CI: 0.42, 0.81; P=0.001) and it was marginal in adults (OR 0.54; 95% CI: 0.28, 1.06; P=0.08). This difference could be attributed to publication bias, low number of trials, different vitamin D doses and heterogeneity of participants.

Martineau et al. (12) included 25 randomized controlled trials, with a total of 10,933 participants aged 0-95 years from 14 different countries. Overall, there was a significant beneficial effect of vitamin D supplementation in decreasing the risk of experiencing at least one acute respiratory tract infection (OR 0.88; 95% CI: 0.81, 0.96; P=0.003). This protective effect was seen in those not receiving bolus doses (OR 0.81; 95% CI: 0.72, 0.91) vs those receiving bolus doses of ≥30000 IU (OR 0.97; 95% CI: 0.86, 1.10). Also, this effect was seen among those receiving doses <800 IU (OR 0.80; 95% CI: 0.68, 0.94; P=0.006) but not those receiving doses 800–2000 IU or >2,000 IU. Furthermore, this protective effect was seen in children 1–16 years (OR 0.60; 95% CI: 0.46, 0.77; P<0.001) but not in those aged 16-65 years or those older than 65 years. In general, there was significant heterogeneity of effect between primary trials.


Applicability of the results

Three of the reviews consistently showed a benefit of vitamin D supplementation for preventing respiratory tract infection mainly in children younger than 16 years (10–12). Two of the reviews also reported that the protective effect is observed only when single daily doses are used but not when bolus doses are given (10, 12). One review further showed that doses of 800 IU or less were protective of respiratory tract infections, but not higher doses (12). However, this protective role was not seen for pneumonia, as reported by Yakoob et al. (9) from only two trials.

It is important to note that most reviews reported significant heterogeneity, which may make the generalizability of the results difficult. This heterogeneity may be due to several reasons, including some publication bias, but also methodological issues, such as low numbers of trials, vitamin D supplementation regime used and heterogeneity of participants’ characteristics. With respect of vitamin D supplementation regime, these reviews showed that the size of the dose and the administration intervals might modify the effects of vitamin D supplementation on respiratory tract infections. Daily smaller doses were more effective than single large boluses of vitamin D. In fact, studies have shown that large boluses may in some cases increase the risk of adverse outcomes, such as increased risk of pneumonia, suppressed proliferative responses of peripheral blood monocytes, suppressed inflammation, and greater positive sputum cultures (13–16). With respect to participant’s characteristics, body mass index as well as baseline vitamin D status may modify the 25-hydroxyvitamin D response to vitamin D supplementation (15, 17, 18).

Implementation in settings with limited resources

Vitamin D supplementation for preventing respiratory tract infection is not routinely done. For this intervention to be effective, it should be done continuously, before the respiratory tract infection starts. This could be a major challenge in many under-resourced settings, as programme managers and policy-makers will have to plan for procurement of the preparation, storage, distribution, quality-control, and compliance assurance of vitamin D supplements for children on a routine basis. Failures in implementation of this intervention have been attributed in many instances to inadequate infrastructure and poor compliance, particularly in developing countries. Intermittent vitamin D supplementation would reduce some of these challenges, although results from these trials show that bolus doses are not effective. Future studies could evaluate the effectiveness of different dosing schemes on respiratory tract infections, such as once a week, which may be easier to implement.

Further research

Additional trials testing different dosing regimen (level of dose and intervals) are needed before implementing this at a population level. Also, trials should follow up participants long enough to understand if vitamin D is still effective once vitamin D status is optimal, as once vitamin D deficiency is corrected, giving more vitamin D supplementation may not provide additional benefits. Currently, there are other randomized controlled trials testing the effects of vitamin D on risk of acute respiratory tract infection, which could help elucidate some of these issues. In addition, future studies need to report adherence to the intervention to better understand if inclusion of non-adherent participants would bias the results reported so far.


1. WHO. Respiratory tract diseases. Geneva: World Health Organization; 2016. (

2. WHO. Pneumonia. Geneva: World Health Organization; 2016. (

3. Jiang X, Sun L, Wang B, Yang X, Shang L, Zhang Y. Health-related quality of life among children with recurrent respiratory tract infections in Xi'an, China. PLoS One. 2013;8(2):e56945.

4. Palacios C, Gonzalez L. Is vitamin D deficiency a major global public health problem? Journal of Steroid Biochemistry & Molecular Biology. 2014;144(2014):138-145.

5. Wahl DA, Cooper C, Ebeling PR, Eggersdorfer M, Hilger J, Hoffmann K, Josse R et al.. A global representation of vitamin D status in healthy populations. Archives of Osteoporosis. 2012;7(1):155–172.

6. Greiller CL, Martineau AR. Modulation of the immune response to respiratory viruses by vitamin D. Nutrients. 2015;7(6):4240-70.

7. Wang TT, Dabbas B, Laperriere D, Bitton AJ, Soualhine H, Tavera-Mendoza LE, et al. Direct and indirect induction by 1,25-dihydroxyvitamin D3 of the NOD2/CARD15-defensin beta2 innate immune pathway defective in Crohn disease. Journal of Biological Chemistry. 2010;285(4):2227-31.

8. Gombart AF, Borregaard N, Koeffler HP. Human cathelicidin antimicrobial peptide (CAMP) gene is a direct target of the vitamin D receptor and is strongly up-regulated in myeloid cells by 1, 25-dihydroxyvitamin D3. The FASEB Journal. 2005; 19(9):1067-1077.

9. Yakoob MY, Salam RA, Khan FR, Bhutta ZA. Vitamin D supplementation for preventing infections in children under five years of age. Cochrane Database Systematic Reviews. 2016;11:CD008824.

10. Bergman P, Lindh ÅU, Björkhem-Bergman L, Lindh JD. Vitamin D and respiratory tract infections: a systematic review and meta-analysis of randomized controlled trials. PLoS one. 2013;8(6):e65835.

11. Charan J, Goyal JP, Saxena D, Yadav P. Vitamin D for prevention of respiratory tract infections: a systematic review and meta-analysis. Journal of Pharmacology and Pharmacotherapeutics. 2012;3(4):300-303.

12. Martineau AR, Jolliffe DA, Hooper RL, Greenberg L, Aloia JF, Bergman P, et al. Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data. BMJ. 2017;356:i6583.

13. Kimball S, Vieth R, Dosch HM, Bar-Or A, Cheung R, Gagne D, et al. Cholecalciferol plus calcium suppresses abnormal PBMC reactivity in patients with multiple sclerosis. The Journal of Clinical Endocrinology & Metabolism. 2011;96(9):2826-2834.

14. Coussens AK, Wilkinson RJ, Hanifa Y, Nikolayevskyy V, Elkington PT, Islam K, et al. Vitamin D accelerates resolution of inflammatory responses during tuberculosis treatment. Proceedings of the National Academy of Sciences. 2012;109(38):15449-15454.

15. Lehouck A, Mathieu C, Carremans C, Baeke F, Verhaegen J, Van Eldere J, et al. High doses of vitamin D to reduce exacerbations in chronic obstructive pulmonary disease: a randomized trial. Annals of Internal Medicine. 2012;156(2):105–114.

16. Manaseki-Holland S, Maroof Z, Bruce J, Mughal MZ, Masher MI, Bhutta ZA, et al. Effect on the incidence of pneumonia of vitamin D supplementation by quarterly bolus dose to infants in Kabul: a randomised controlled superiority trial. Lancet. 2012;379(9824):1419-1427.

17. Martineau AR, James WY, Hooper RL, Barnes NC, Jolliffe DA, Greiller CL, et al. Vitamin D3 supplementation in patients with chronic obstructive pulmonary disease (ViDiCO): a multicentre, double-blind, randomised controlled trial. The Lancet Respiratory Medicine. 2015;3(2):120-30.

18. Drincic AT, Armas LAG, van Diest EE, Heaney RP. Volumetric dilution, rather than sequestration best explains the low vitamin D status of obesity. Obesity. 2012;20(7):1444-1448.


The named authors alone are responsible for the views expressed in this document.

Declarations of interests

Conflict of interest statements were collected from all named authors and no conflicts were identified.





Now that you have read this story, please COVER THE COST for what your visit cost this site by clicking one or more of the ads below which generates Advertiser revenue of two to three cents per click - no purchase necessary by you -- and helps offset operating costs for this web site.

When YOU read a story here, the web hosting company charges us for "data transfer / Bandwidth" to convey the material to you.  Without your help by clicking an ad below, this web site would be in danger of shut down from the data transfer charges.  Please click any ad below to offset the cost of bringing this news to you.

You must login to post a comment.
Loading comment... The comment will be refreshed after 00:00.
  • This commment is unpublished.
    TL Spurlen · 1 months ago

    8. Conclusions and Perspectives
    Viruses such as HIV, HSV, influenza viruses, and cold viruses infect and kill millions of people every year. Severe acute respiratory syndrome, avian flu viruses, Middle East respiratory syndrome corona virus, Ebola virus, and many others are still without treatments and some may become global pandemics if not urgently addressed. The few vaccines available against some of these viruses need to be updated every year, and never reach the majority of people in developing nations. Antibiotics are designed to reach and stop the replication of bacteria without crippling the vital cellular genetic machinery. By contrast, most viruses have the ability to hijack the cell genetic machinery inside the nucleus in order to replicate. This explains why antibiotics are often ineffective against many viral infections such as the flu, cold virus, and many others. The creosote bush lignans possess the ability to act at the cellular level and permeate the nucleus and the virus envelope to block the viral gene machinery.21 They are capable of suppressing viruses that contain Sp1 or are rich in C/G boxes in their gene transcriptional machinery such as HSV, varicella zoster virus, blindness-causing cytomegalovirus, HIV, and HPV. Since Sp1 and C/G motifs are common features in many virus families and are highly conserved (nonmutable), this class of plant lignans could represent a breakthrough for viral treatment as penicillin became for bacteria since World War II.
  • This commment is unpublished.
    Patricia Davis · 1 months ago
    I started using monolaurin in 2006 and have had many occasions to experience firsthand how well it works. I've used it to squelch dental abscesses four times, which usually takes 3-4 days. I've given it to a cat with a severe inner ear infection -- cleared it in 8 days. I took it for an H. pylori stomach ulcer, cured it in a week. A friend who is an herbalist by profession used it to cure a cat of cytauxzoonosis felis (Bobcat fever, caused by a bite from a tick carrying the protozoa) which is 95% fatal even with veterinary treatment. I emailed Hal about it seven days before he mentioned it on the show. I've heard of it curing C-DIFF. It's really great stuff. It's also available in capsules. The pellet form is great for animals because it can be mixed into their food, but for human beings the capsules work just as well as the pellets.
  • This commment is unpublished.
  • This commment is unpublished.
  • This commment is unpublished.
    Paul Andrews · 1 months ago
    Colloidal silver!!!
    spray it in your eyeballs, the fastest way to get it in the bloodstream without syringe. Sip some in your mouth and let it sit there as long as you can. The veins under your tongue will absorb it. Colloidal silver kills viruses on contact
  • This commment is unpublished.
    James Huff · 1 months ago
    Vitamin D and pineapple juice are two things you will want to have in your inventory. If you have kidney problems, lemon juice or lemonade made with real lemons. The Vitamin D helps with respiratory issues. The pineapple helps as an anti-inflammatory and lemon juice breaks up crystalline particles which form kidney stones. (not everything works for everyone, but this will help most people.) ** Disclaimer: I'm not a doctor, just in a family with a bunch of medical professionals in it. End of Disclaimer**
    • This commment is unpublished.
      Gregg Walker · 1 months ago
      Okay. From all the comments here, I’m hearing : Pineapple juice + coconut milk is a good protection from this. Sounds to me like Pina Coladas are on the menu!
      The alcohol probably helps in some way.
  • This commment is unpublished.
    Tom Martin · 1 months ago
    I live in South Florida - gonna layout in the sun again today and get as much D as I can.
    • This commment is unpublished.
      Gregg Walker · 1 months ago
      Lucky you! It’s rainy and cool outside Seattle - AKA - Ground Zero!!
  • This commment is unpublished.
    jw williams · 1 months ago
    This is imperative: ALWAYS ask your doctor or pharmacist if this or anything else is ok to take with your other medicines.
  • This commment is unpublished.
    Texas Aggie · 1 months ago
    You can buy this directly from the company here...
    When i purchased, they had a special on 6 of them for about $150. I ordered march 3rd and they are scheduled to be delivered march 7th via the post office. If you take it per their directions (1 scoop 3x daily, the 8oz container holds 75 scoops) each container should last 25days.
    • This commment is unpublished.
      Texas Aggie · 1 months ago
      Amazon is showing that the individual 8oz containers are about $35 each. The company also pre-warns you that you will have an adjustment period (sort of like the keto-flu) for the first few days. I have not experienced this but i eased into taking it per their suggestion.
  • This commment is unpublished.
    Sedge Hammer · 1 months ago
    Are you taking it now Hal or waiting till you think your infected? Plus what amount will you be taking? Thanks
  • This commment is unpublished.
    H H · 1 months ago
    If you can't buy this product, find cold pressed coconut oil.

    "Monolaurin is a chemical made from lauric acid, which is found in coconut milk" and (Monolaurin is a chemical derived from lauric acid, a component of both coconut fat breast milk)
    • This commment is unpublished.
      Patricia Davis · 1 months ago
      The product is very easy to find. To get the equivalent effect using coconut oil, you would need at least six Tablespoons per day, which would cause big digestive problems.
  • This commment is unpublished.
    BU · 1 months ago
    Off topic: when I post I get notifications that folks are responding to them.. but when I click on the responses it just says error 404... does everyone have that issue?
    • This commment is unpublished.
      Patricia Davis · 1 months ago
      I have the same.
    • This commment is unpublished.
      Occams Razor · 1 months ago
      I've had that issue on my Mac. Seems to be an issue with the Javascript not concatenating the reply url correctly, there is a redundant en/index.php or something like that that needs to be removed in the url string, and then it will take you to the right place. I wrote Hal about this issue a while back, it's very annoying.
  • This commment is unpublished.
    Henry Swarey · 1 months ago
    Hal, concerning Chloroquine and Quinine, here is the article and an excerpt from a US government website. Bottom line is THE US KNOWS THAT CHLOROQUINE/QUININE INHIBITS CORONA VIRUS AND INFLUENZA REPLICATION! Why are they sitting on this information? WHY ARE YOU SITTING ON THIS INFORMATION???

    Researchers at KU Leuven in Belgium have discovered that the existing malaria drug chloroquine works against COVID-19, the disease caused by the corona virus. reports this.The drug chloroquine has been on the market since 1934. In 2004 the Belgian professor Marc van Ranst discovered that the medicine works against SARS. He wondered if it would work against the current coronavirus 2019-nCoV. That turned out to be the case.
    In ten hospitals in Beijing, Hunan and Guangdong, the malaria drug has been tested on patients infected with the COVID-19 corona virus. Experts from the Chinese Ministry of Science and Technology reported Monday that the drug works.
    In patients receiving chloroquine for a week, the fever decreased and the lung function improved. Soon they were virus-free and cured, reports KU Leuven. It is the first time that there is a means by which corona patients can be cured. For this, doctors could only combat the symptoms of the virus.
    The malaria agent can be used until a vaccine against the corona virus is available. However, it will take another two years for the vaccine to be applied to humans. "Fortunately, chloroquine can be produced easily and cheaply in large quantities," says Van Randst.…/oud-malariamiddel-werkt-teg…
    Effects of lysosomotropic agents on influenza A virus replication
    We first compared the efficacy of novel LAAs to interfere with IAV replication in a viral plaque inhibition assay in MDCK cells which provides a direct evaluation of ability of compounds to block viral plaque formation. In agreement with previous studies [20], [26], bafilomycin A and chloroquine completely inhibited the replication of PR8, X-31, and A/H1N1/2009 in the low micromolar range (Fig. 1 B–C, Table 1). Moreover, all the other LAAs were also able to significantly interfere with PR8 replication in a dose-dependent manner (Fig. 1 A, D–H). All LAAs inhibited IAV replication at a dose range below 10 µM, except quinidine, which had to be used at least at 16.2 µM ( Fig. 1). At the lowest concentrations giving rise to maximal inhibition of PR8 viral plaque formation, all LAAs tested showed no cytotoxicity except for quinacrine (10% cell death at 6.5 µM but no toxicity at 4 µM; Figure 1 and Table 2, and data not shown). Furthermore, even though quinine had a higher EC50 than mefloquine, it was able to completely abrogate PR8 replication at a higher concentration, which was not the case for mefloquine. In general, compared to chloroquine, amodiaquine and quinacrine showed similar antiviral activities against influenza viruses. Interestingly amodiaquine was the most active against X-31, chloroquine was the most potent against PR8 whereas amodiaquine and quinacrine were more effective against the A(H1N1)pdm09 virus. Overall, among the new compounds tested, we demonstrated that amodiaquine is the most potent, followed by quinacrine, mefloquine, quinine, quinidine, and primaquine. In addition to its antiviral activity determined in viral plaque formation inhibition assay, amodiaquine also inhibited viral replication in growth kinetics assays (Figure S1). Moreover, additional experiments with amodiaquine were performed in a human bronchial epithelial cell line (Calu-3) that represents a more physiologically relevant primary target for influenza virus infection. Interestingly, the results obtained with this cell line matched those obtained in MDCK cells. Indeed, in Calu-3 cells, the EC50 of amodiaquine against PR8 is between 1.25–2.50 µM compared to an EC50 of 2.76 µM in MDCK cells (Table S1).
    • This commment is unpublished.
      Jeff Goldring · 1 months ago
      I don't think this is accurate and I wouldn't use Chloroquine. I did some of my own research and hears what I figured out. 1. Don't take any vaccine or anti-viral medication (including chloroquine) as this opens receptors on the virus for the second infection to make it WORSE or MORE DEADLY. 2. In doing my research, because this is a bioweapon, it is pre-disposed to act differently than other viruses. 3. The baseline of this research I did was based on the fact that the virus causes a cytokine storm in the body (which is essentially what kills people about this virus). Cytokine storm is caused by a histamine reaction to the virus which basically makes your body attack itself. The body creates DAOs (diamine oxidase) to fight the cytokine storm. DAO's ability to fight the cytokine storm is INTERRUPTED and INHIBITED by malarial and antibiotic drugs. Chloroquine is a malarial drug.
    • This commment is unpublished.
      Standing Wave · 1 months ago
      A problem remains (OK, maybe more than one problem remains): How does one convert µM in the assay to mg dose, especially for chronic prophylaxis.
    • This commment is unpublished.
      Standing Wave · 1 months ago
      KP - The link to yields Pagina niet gevonden, which I suspect means "Page not Found".
    • This commment is unpublished.
      Occams Razor · 1 months ago
      I think that Hal should have a "Useful links", a community bulletin board of links instead of all these freaking ads polluting the forums. I would chip in an extra dollar a week to get rid of all that stuff.
    • This commment is unpublished.
      Henry Swarey · 1 months ago
      .Here it is in black and white! Furthermore, even though quinine had a higher EC50 than mefloquine, it was able to completely abrogate PR8 replication at a higher concentration,
      • This commment is unpublished.
        Rhonda Doerr · 1 months ago
        I bought the bark and the capsules and tincture. Thank you for sharing. PRAISE YEHOVAH for giving us medicine! HALLELUYAH!
      • This commment is unpublished.
        Henry Swarey · 1 months ago
        EC50 means Half maximal effective concentration. Does anyone know what "Completely abrogate means??? Wake the hell up people! Print out the above and take it to your local health dept. They will be dumbfounded.
  • This commment is unpublished.
    Sam · 1 months ago
    ******Personal Protective Equipment Training - RESPIRATORS
    To effectively use an air purifying respirator, it is not enough to just have bought a box of random n95’s. You need to know the lifespan of the respirator in the environment they are being used, and you need to really be fit tested to ensure a proper seal. A 3M half mask with 100 rated cartridges is much better, and a 3M full face mask is even better than that, having sealed eye protection built in. When Dave Hodges recently interviews “Wrecker”, he noted that a disposable n95 may need to be changed hourly after reaching saturation.
    Here is a sample link of respirator training:
    To really do this right, you likely should have at least a full face respirator, know the limitations and cartridge life of that respirator, and have some sort of decontamination zone with showering capabilities. There is much more necessary to maintain a level 4 protection, and you may begin to realize that you have not sufficiently prepared if you were trusting that you are covered in this area.